loading page

Assessment of PD-L1 Expression in Patients With Neuroblastoma and Renal Tumors
  • +2
  • Seher Sener,
  • aylar poyraz,
  • Arzu Okur,
  • Faruk Pınarlı,
  • Ceyda Karadeniz
Seher Sener
Gazi University Faculty of Medicine
Author Profile
aylar poyraz
gazi university
Author Profile
Arzu Okur
Gazi University Medical School
Author Profile
Faruk Pınarlı
gazi university
Author Profile
Ceyda Karadeniz
Gazi University Medical Faculty
Author Profile

Abstract

Introduction: Programmed death 1 (PD-1) is a co-receptor which is located at the surface of cells like natural killer, monocytes, T and B cells. It has two ligands including programmed death ligand-1 (PD-L1) and ligand-2 (PD-L2). T cell functions are inhibited by activation of PD-1/PD-L1 pathway and this pathway is used by viruses and some tumor cells in order to escape from immune eradication. In our study we evaluated PD-L1 expression in the tissue specimens of patients with Wilms tumor, neuroblastoma and other renal tumors. Material and Methods: Totally 60 patients who were followed up at Gazi University Hospital with the diagnosis of neuroblastoma, Wilms tumor and other renal tumors were included. PD-L1 expression was examined in tumor samples of the patients. Results: Positive staining with PD-L1 was detected only in two male patients. Both of them had neuroblastoma and advanced stage disease. None of the patients with Wilms tumor and other renal tumors had positive PD-L1 staining. Conclusion: Unlike adult tumors; PD-L1 expression is not common in childhood tumors due to differences in immune system between children and adults. Further studies are needed to establish the importance and effects of PD-1/PD-L1 pathway in pediatric tumors.